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Abstract
Moyamoya disease is a rare cerebrovascular disease most prevalent in East 
Asian Countries. Thanks to the new diagnostic capabilities, the number of cases 
discovered has been rising steadily in the latest years, including many asymptomatic 
patients. But asymptomatic from the clinical point of view does not necessarily 
mean that there are no subjacent problems and that there will be no disease progres-
sion. Indeed, many patients harbour cognitive decline long before they start with 
clinical or even radiological manifestations. The only effective treatment is surgical 
revascularization, with all its possibilities: direct, indirect, and combined. While 
direct techniques are more useful in adult moyamoya patients, children seem to 
benefit most from indirect techniques. Additionally, indirect or combined proce-
dures can be used as salvage procedures in case of unsatisfactory outcomes. Thus, 
many surgeons posit that surgical treatment should be considered in moyamoya 
patients, even if asymptomatic, particularly in the paediatric age group.
Keywords: moyamoya disease, surgical revascularization, bypass surgery,  
asymptomatic moyamoya disease, cerebral revascularization, treatments modalities
1. Introduction
Takeuchi and Shimizu first described Moyamoya disease (MMD) in 1957 [1]. 
It is an idiopathic cerebral vasculopathy characterised by progressive stenosis of 
the terminal internal carotid artery and its branches, usually on both sides, and 
the development of a compensatory network of abnormal collateral vessels [2]. 
Unilateral involvement does not rule out this disease [3]. It affects mainly the 
middle (MCA) and anterior cerebral (ACA) arteries, less commonly the posterior 
cerebral or the middle meningeal arteries, and in a few cases the arteries that supply 
other organs [4], like the lungs or kidneys [5]. Some MMD patients suffer from 
pulmonary artery hypertension, which usually starts in adolescence or young adult-
hood and progresses slowly [5].
The collateral vessels that develop as the disease progresses [6] have a thin and 
weak non-elastic wall with aneurysm formation prone to haemorrhages [7–9]. These 
aneurysms’ prevalence varies in the different series between 1.9 [10], 2.8% [11], 3.9 
[12], 8.3 [6] and 14% [13]. They are usually located in deep areas [11], small in size and 
with very fragile walls, making their treatment, endovascular or surgical, extremely 
challenging [11, 12, 14]. They can also be found at the circle of Willis [9, 11, 15, 16], 
where they usually have a fusiform shape [11, 17] and can lead to a subarachnoid 
haemorrhage [11]. The prognosis in the case of this type of haemorrhage is poor [11]. 
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Their recommended treatment is brain revascularization (BR) [12, 18, 19] as many 
regress spontaneously after their haemodynamic stress is reduced [11, 20–24].
MMD can be associated with other diseases like Down syndrome (trisomy 21)  
[25], sickle cell disease [26], neurofibromatosis type 1 [27], thalassemia [28], 
Graves’ disease [29] and after head- and neck-radiotherapy [30]. In this case, it is 
known as moyamoya syndrome [3].
MMD patients have impaired cerebral haemodynamics with a low cerebral 
blood flow (CBF) or a poor brain vasodilatory capacity, making them prone to 
cerebrovascular events [31], particularly at the frontal lobe [32]. The CBF and the 
cerebral vascular reserve (CVR) capacity are used to evaluate the need for surgical 
treatment [33–36].
Although it is a rare disease, it is the leading cause of ischemic stroke in the 
paediatric population in Korea and Japan [37–39].
Digital subtraction angiography (DSA) is the gold standard for diagnosis, but 
Magnetic Resonance Angiography (MRA) is also helpful [40, 41]. More specific 
methods but not currently used because of the costs and equipment involved are 
xenon-enhanced CT, DSC, MRI, H2[ [15]O]-PET and [42] I aromatic amines SPECT 
[43–48]. These diagnostic techniques are used for preoperative evaluation to decide 
the best surgical approach. Their drawbacks are that they require contrast agents’ 
intravenous injection and entail radiation exposure that can be harmful to patients, 
particularly in the paediatric age group. Preoperative transcranial colour-duplex 
sonography is a non-invasive method used to evaluate the degree of vascular 
impairment in MMD and monitor the results after surgical BR [49–51].
The patients’ mean age at diagnosis peaks at ten and 30–50 years [9, 12, 52] with 
a ratio of women-to-men 1.00:1.03 [12].
MMD two basic clinical manifestation types are ischemic (30.4%) and haemor-
rhagic (70.9%) stroke [12]. The ischemic type is more common in children and 
the haemorrhagic in adults [13, 53]. Other clinical symptoms are headache [54], 
epilepsy [55], chorea movements [56] and cognitive decline [53, 57]. In comparison, 
haemorrhages are more frequent in the adult MMD population [58] and ischemic 
events in the paediatric age group [59–62]. Patients starting with ischemic symp-
toms like transitory ischemic attack (TIA) are more prone to develop an ischemic 
than a haemorrhagic stroke [63, 64]. In the paediatric population, multiple ischemic 
strokes, significantly if both hemispheres are affected, can lead to severe cognitive 
impairment and developmental delay [65–67]. Brain infarcts present in the ACA 
and MCA territories and less commonly in the posterior cerebral artery (PCA) cov-
ered area and vertebrobasilar system [68]. Posterior circulation involvement leads 
to more severe symptomatology and worse outcomes [69]. Haemorrhagic strokes 
are often followed by rebleeding and infarction in short to medium follow-up [70].
Unless surgical BR is undertaken, the stroke rate is 18% for the first year and 
3.2–5% for the following years [71–73]. Once patients suffer an ischemic or haemor-
rhagic stroke, the risk of a new cerebrovascular insult in the following five years is 
65% [74, 75].
In MMD, the PCA provides the collateral flow to the anterior circulation  
[32, 76–79] with choroidal anastomosis and hypertrophic collateral vessel forma-
tion [76, 80]. This increased blood flow through the PCA creates haemodynamic 
stress on the vertebrobasilar system and facilitates aneurysm formation [76, 81]. 
The choroidal collateral vessels are potential sources of haemorrhages and rebleed-
ing [82]. A common complication is a brain haemorrhage [80, 83, 84], usually 
intraventricular [80, 85], particularly in the rear brain areas [80]. Moreover, MMD 
patients with haemorrhages in the posterior part of the brain have a higher risk of 
rebleeding than those with haemorrhages located in the anterior part [85]. PCA 
stenosis is typical of juvenile-onset MMD [86].
3
Surgical Treatment of Moyamoya Disease
DOI: http://dx.doi.org/10.5772/intechopen.99776
Microbleeds’ are more common in MMD than in the general population [87] 
and usually in the periventricular areas, followed by the basal ganglia and thala-
mus [87–89]. The asymptomatic microbleeds are related to hypertrophy, dilatation 
and aneurysm formation of the posterior communicating and anterior choroidal 
arteries [90–92]. Those areas are where the MMD related haemorrhagic strokes 
typically happen, and these microbleeds are an excellent prognosticator of future 
haemorrhages [83, 93, 94].
Asymptomatic MMD patients have a 3.2% annual stroke risk [95], more often 
haemorrhagic than ischemic, showing an evolving situation that is usually is not 
silent nor stable [72, 96], particularly in those with a compromised CVR capacity 
[97]. Moreover, cognitive decline over time is the rule [98]. Thus, asymptomatic 
MMD patients should be monitored closely and submitted to surgical BR at the 
slightest sign of deterioration [99].
Although there might be a subgroup of children with a benign course [100], 
most have a relentless and progressive worsening [99], and unilateral disease often 
evolves to bilateral [99]. Predictors of unfavourable outcome are onset at a younger 
age, a long time before BR, brain infarcts, and PCA involvement [86]. Children 
under nine years of age with minor changes in the contralateral brain hemisphere 
are most likely to undergo disease progression [101, 102].
This disease, particularly if untreated, can induce severe disability and even 
death [3]. White matter involvement, particularly in adults, correlates with cogni-
tive impairment [57].
2. Treatment modalities in moyamoya disease
Without a known aetiology, the only treatment is symptomatic. The medical treat-
ment does not affect this disease’s relentless progression [103, 104], and patients under 
drug treatment alone have a 5-year 65% stroke risk [72, 105–107] which climbs up to 
a dismal 82% in case of bilateral involvement [105]. In children, it has been reported 
that under conservative treatment, 37% will present clinical symptoms of neurologi-
cal damage, and 3% will eventually die [108]. It can be helpful, though, to alleviate 
some symptoms like headache or epileptic seizures [109]. Endovascular treatment 
has been attempted in some cases with unsatisfactory results [110–112]. The surgi-
cal treatment with BR offloads the haemodynamic stress [113] and reduces the risk 
of subsequent ischemic and haemorrhagic cerebrovascular events [104, 114–122], 
providing symptom improvement to 87% of patients [104].
BR techniques can be classified into two main groups: direct and indirect. The 
first involves artery-to-artery bypasses between an external carotid artery branch 
and a brain arterial vessel, usually between the superficial temporal (STA) and 
MCA [42, 115, 123]. Other donor vessels are the occipital [69, 124], deep temporal, 
and middle meningeal [125] arteries. The STA can be connected to a branch of the 
middle cerebral [126] or anterior cerebral [127] arteries. Meanwhile, the occipital 
artery is sutured to the PCA [128] but can also be used to revascularize the MCA 
territory [129]. The size of the donor artery should be >0.8 mm to allow the surgical 
manoeuvres [130]. In children under four years of age, both the STA and the pos-
sible recipient brain arteries usually have an insufficient diameter to enable a bypass 
[131]. Its most significant advantage is that it provides immediate brain haemody-
namic improvement. This fast improvement in the brain blood flow reduces the risk 
of ischemic and haemorrhagic strokes faster than the indirect techniques, which 
require 3–4 months to achieve the same result [132]. Its main risk is a hyperper-
fusion-reperfusion syndrome, which can induce haemorrhages with neurological 
deterioration and worsening [115, 133, 134]. This risk can be minimised with strict 
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postoperative blood pressure control and mild hypotension in symptomatic cerebral 
hyperperfusion [135]. Direct BR is mainly used to increase the perfusion of the 
MCA territory [99]. Direct BR of the anterior or PCA branches is challenging as the 
donor’s vessels are further away, a severe problem when those vascular territories 
are affected [99]. Under experienced hands, the patency rates are over 90% [136]. 
As the cortical arteries atrophy, it is increasingly difficult to find a suitable recipient 
vessel to perform a direct bypass [137]. The ideal is an M3 branch, but micro-anasto-
moses with these vessels are technically very difficult [138].
In the indirect BR, no arterial anastomoses are performed. Instead, a pedicle 
graft vascularized by the external carotid artery is placed over the brain’s surface 
and rely on the new collateral vessel formation between the donor tissue and 
the ischemic underlying brain [139]. For a successful result, three elements are 
needed—first, a well-vascularized donor tissue. Second, intimate contact between 
donor tissue and recipient brain vascularization. And third, a good selection of 
the hypoperfused recipient brain areas [140]. Indirect BR requires forming a 
fibrous scar at the donor tissue-brain interface with new collateral vessel formation 
between the donor and recipient vascular beds [141]. The possibilities of indirect 
BR techniques are broad [104]. Depending on the donor tissue used, the options 
are encephalo-myo-synangiosis (EMS) [142] when a muscle is used, encephalo-
duro-synangiosis (EDS) [143] with dural graft, split-duro-encephalo-synangiosis 
(DES) [144, 145] with a split dura graft, encephalo-duro-myo-synangiosis (EDMS) 
[146] with dural and muscle graft, encephalo-duro-arterio-synangiosis (EDAS) 
[147–150] with dura and external carotid artery branch, encephalo-duro-arterio-
myo-synagiosis (EDAMS) [151] with dura, an external carotid artery branch and 
muscle, encephalo-galeo-synangiosis (EGS) [152, 153] with galea, encephalo-
pericranium-synangiosis (EPS) [140, 154, 155] with pericranium, omentum 
transplantation [156, 157] and multiple burr-hole (MBH) [158, 159]. This last 
surgical technique consists of performing numerous burr holes (10 to 24) through 
the frontal, parietal and occipital bones, opening the dura and arachnoid and 
introducing a pericranium flap inside each burr-hole [160]. It can be used iso-
lated, as part of other BR techniques or as a rescue procedure when other surgical 
approaches have failed or proved insufficient [160–162]. Not only is it technically 
effortless and straightforward, but it can be performed under local anaesthesia, 
which is an advantage in patients in a seriously compromised status [161]. As the 
dura is also an essential source of collateral vessel formation, a small craniotomy 
(3–3.5 cm in diameter) placing the pericranium directly over the brain surface pro-
vides better results than MBH [140]. Contrarywise, extensive craniotomies are not 
recommended because they disrupt the already spontaneously formed collateral 
vascularization increasing the risk of postoperative brain ischemic events [140]. 
The EPS is particularly helpful to provide collateral circulation to the anterior and 
PCA territories, areas not easily covered by the STA [140]. Duropexy is crucial in 
all indirect BR techniques [140].
Direct BR is preferred whenever possible because the haemodynamically compro-
mised hemisphere gets an immediate increase in blood flow, reducing sooner the isch-
emic and haemorrhagic stroke risk [113, 163]. In contrast, with the indirect techniques, 
the new collateral vascularization takes 3 to 4 months to develop [53, 164, 165], but 
long-term, the blood–brain supply is better than with the direct BR [141]. In this period 
in which the collateral vessel formation is taking place, may persist brain hypoperfusion 
symptoms, and at times the final result may require an additional surgical BR  
procedure [128, 166–168].
With the direct bypass, the brain perfusion improvement is limited to the area 
where it is undertaken and is not helpful to perfuse extensive ischemic areas [169]. 
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Contrarywise indirect brain vascularization can cover vast vascular territories, mainly 
if different techniques are employed, like the EDAS combined with MBH [5, 159]. 
This combination can provide new blood supply to the whole brain, including the 
interhemispheric frontal areas and occipital lobe [68].
MMD related aneurysms were treated with embolization or surgical clipping 
[11], and many improved with BR alone [11, 12].
3. Historical development of surgical BR for MMD
Yaşargil performed the first superficial-temporal artery bypass procedure for 
an MMD patient in 1972 [170]. In Japan, the first case was completed in 1973 by 
Kikuchi and Karasawa [171]. In the following years, Karasawa and colleagues in 
Japan refined this surgical procedure and reported their results in 1978 [123].
The first indirect MMD BR was reported by Karasawa in 1977 and was called 
encephalo-myo-synangiosis (EMS) [142]. Several researchers confirmed that 
placement of the temporalis muscle directly over the brain induced collateral vessel 
formation [172–174]. In 1980 Matsushima et al. introduced a new indirect BR 
technique, the EDAS [175]. The STA with a strip of its surrounding galea was placed 
directly over the brain through a linear dural incision [176]. The galea was sutured 
to the dural edges, and the STA left over the brain without interrupting its flow, 
waiting for collateral vessel formation between the dura, the galea, the STA and 
the brain. It became widely accepted [149, 153, 177–180]. The EMS was the ground 
stone for other indirect BR techniques introduced in the following years that used 
different donor tissues, including other scalp arteries [177], split dura [145], neck 
[181] or distant [182–184] muscles and the omentum [156]. Others reported using 
the pericranium introduced though multiple burr-holes [185]. These techniques 
revascularized the MCA territory but not those of the anterior and posterior cere-
bral arteries. In 1992, Inoue et al. [186] introduced the frontal EDAMS to selectively 
revascularize the anterior cerebral bed to overcome this drawback. Kinugasa et 
al. [187] two years later reported the ribbon EDAMS, in which a strip of galea and 
pericranium were placed over the frontal lobes, including the interhemispheric 
areas. Tenjin et al. [177] published in 1997 the occipital artery’s use to revascularize 
the PCA territory. Ever since a combination of direct and indirect BR techniques is 
recommended to achieve a good collateral flow in all three brain arterial territories 
(anterior, middle, and posterior cerebral arteries).
4.  Indication of surgical techniques for cerebral revascularization in 
moyamoya disease
The hemisphere with the worse vascularization is operated first [12]. If both 
hemispheres are equally affected, the recommendation is to start with the dominant 
one and revascularize the other six months latter [178].
In unilateral involvement, if the patients’ symptoms disappear with the unilat-
eral BR and an asymptomatic contralateral hemisphere, no further brain vascular-
ization is advised for the time being [12] as contralateral hemisphere surgical BR in 
patients with unilateral involvement is controversial [99]. In an ischemic or haem-
orrhagic stroke, surgical BR is delayed for at least six weeks [188], and ideally, three 
months [12] and the BR of the contralateral cerebral hemisphere postponed at least 
4–6 weeks [148]. Nevertheless, delaying surgical treatment is not advisable in late 
Suzuki stages [2], as BR improves brain collateral vascularization but not the stroke 
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rate [178]. So, once the diagnosis is made, it is better to avoid unnecessary delays, 
particularly in children [178].
Direct BR is particularly indicated in adult and adolescent MMD patients [189, 
190] but not recommended before ten years of age [191]. An STA to MCA bypass is 
strongly advised as it corrects the MMD related hemodynamic insufficiency [71, 121]. 
For a successful result, both the donor and recipient arteries must be at least 0.8 mm 
in outer diameter [192].
Indirect techniques are much less demanding [193] but are not as valuable for 
adults as for children [99, 149, 150, 152, 159, 179, 194, 195]. Its main drawback is that 
BR takes time, on average 3–4 months [196], during which there is a continued risk 
of cerebrovascular events [140]. In the paediatric age group, these indirect surgi-
cal techniques are preferred because the vessels are often of insufficient size and 
maturity to safely allow a direct arterial bypass [197], significantly below ten years 
of age [198]. One of the main advantages of indirect BR is the possibility of improv-
ing the anterior and PAC territories’ blood perfusion apart from the area covered 
by the MCA [146, 199]. This possibility of a wider area covered by the BR is crucial 
in children [99, 152, 158] as they often develop long-term symptoms secondary to 
hypoperfusion of the whole hemisphere [99]. The BR that use the temporalis muscle 
is not recommended in children [200] because it thickens with time, compressing 
the brain and inducing ischemia [201] and because it adheres to the brain and when 
it contracts can cause long-term neurological damage [202]. Additionally, it gener-
ates an unsightly cosmetic head [200].
A combination of direct and indirect BR procedures is often used to profit from 
the advantages of each of them [34, 114, 136, 150, 160, 203], because the reported 
results are better than isolated direct or indirect techniques [204–207]. The treat-
ment strategy has to be tailored to the specific needs of each patient [136, 160, 208]. 
Combining more than one indirect BR techniques has similar mortality and mor-
bidity as any of them isolated [136].
During the surgical procedure, it is essential to avoid hypotension, hyperther-
mia, hypocarbia, hypercarbia, and epileptic seizures as they all increase the brain 
metabolism and thus the chance of an ischemic event [148, 149, 188, 200, 209–211] 
and perioperative morbidity [212]. It is vital to control the pain and cry in the 
postoperative period to avoid hyperventilation as this will produce hypocarbia and 
an increased risk of ischemia [149, 213]. It is recommended to provide intravenous 
fluids at 1.5 times the regular maintenance rate for 48–72 hours [3, 149]. Platelet 
counts and prothrombin time must be monitored and controlled with transfu-
sions if needed [148]. The blood haemoglobin must be kept above the 12–13 g/dL 
range [148].
Some improvements in the surgical technique have eased the surgical manoeu-
vres and improved the clinical results. Among them is placing 10-0 Proline sutures 
to the arachnoid membrane in both sides of the brain sulcus. When some retraction 
is applied, the recipient artery is brought to the surface, and the STA to MCA bypass 
is made more easily [192].
While it seems intuitive that arachnoid removal will improve the collateral 
vessel formation between the donor artery or tissue and the brain [153], it is no 
longer recommended in indirect BR because it is associated with a significantly 
higher complication risk with no improvement in the final clinical outcome [148]. 
Among these complications are the postoperative ischemic strokes secondary to the 
vasospasm induced by the arachnoid dissection [148]. Preserving the arachnoid 
membrane reduces the operating time at an average of 30 minutes [148].
The middle meningeal artery provides a vital source of collateral circulation, 
so during the surgical procedure, this artery and its main branches should be 
preserved as much as possible [191]. Preservation of this crucial source of collateral 
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vessel formation requires gentle dura handling and careful planning of any dural 
incisions.
Some have recommended medical treatment for asymptomatic MMD because it 
is associated with a 5.3% rate of clinical progression [97] unless they have reduced 
cerebral vascular reserve [97, 103, 214] or smoke [97, 215]. Most of these asymp-
tomatic patients will undergo disease progression [103, 216]. When that happens, 
surgical BR is advisable [95, 103, 215].
In case of failure to initial BR, a new procedure, direct, indirect or combined, 
should be attempted, as good outcomes are common [166, 217].
5.  Results surgical techniques of cerebral revascularization in moyamoya 
disease
BR decreased both the haemorrhagic [115] and the ischemic stroke [164, 218], 
but it is more effective in the first than in the second [219–221]. On one-year 
follow-up, haemorrhagic stroke was 4.6% for those who underwent BR versus 
18.6% for those managed conservatively [115, 116, 164, 219]. The mortality rate due 
to haemorrhagic stroke is four times higher in the conservative than in the BR group 
[116, 164, 220]. The medical treatment had even worse results in the paediatric than 
in the adult MMD age group [107, 222].
Younger age at BR surgery correlates with better results and long-term prognosis 
[62, 164, 205]. In children, indirect BR is associated with a 0.4%/year symptomatic 
haemorrhage and 0.2%/year infarction rates, with cumulative incidences of 1.8% 
at ten, 7.3% at 20 and 7.3% at 30 years [223, 224]. There are no statistically signifi-
cative differences in clinical outcome between direct, indirect and combined BR 
procedures [99, 205]. The average good clinical outcome is 84.8–88% [143, 205] 
with a 6.4% 5-year risk of ischemic or haemorrhagic stroke [143]. Children seem to 
improve more than adults (93% versus 82.7%) [205].
Direct BR with extra-intracranial artery bypass significantly decreases the 
haemorrhagic stroke rate [115, 223], particularly in the patients with haemor-
rhages in the posterior half of the brain [85]. Compared to indirect procedures, it 
reduces the stroke risk [116, 205, 219, 221], particularly the haemorrhagic type in 
adults [225] and adolescents [196]. These differences are not so evident in children 
as adults due to the technical difficulty in performing a successful arterial bypass 
in the first group [140]. Both in adults and the paediatric population, direct BR is 
technically more challenging that indirect BR, demands a longer operating time, 
and there is always the risk of hyperperfusion syndrome [116]. There no statisti-
cally significative difference in the number of perioperative complications between 
direct and indirect BR techniques [219]. The direct bypass was accompanied by 
an annual stroke rate of 0–6% for children and 1.4% for adults, while the indirect 
techniques had a 1.6% stroke rate for the same period of time [196]. Direct BR is 
recommended whenever it is technically feasible [197, 221].
Indirect BR is easier to perform, but 40–50% of adult MMD patients do not 
develop an adequate collateral arterial circulation [53, 62, 141, 226]. These results have 
been improved with changes in the surgical technique and perioperative care [140], 
but a new surgical procedure with a combined approach will be needed if there is an 
unsatisfactory outcome [189, 207, 224]. Meanwhile, paediatric patients submitted to 
indirect BR have low middle and long term haemorrhagic stroke rates [227, 228].
Perioperative complications happen in 9.4–13.6% of BR procedures [116, 149, 
194, 205, 219, 221, 226] with a 0–0.5% [188] mortality rate. Indirect BR has a 
significantly higher postoperative stroke rate than direct techniques [116, 205] 
but fewer haemorrhages and no hyperperfusion syndrome [140, 229, 230]. The 
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incidence of postoperative surgical complications is higher in Asian than other 
racial groups (6.51/100,00 inhabitants/year versus 5.21/100,000/persons/year) 
[198, 231]. They also show a different response to BR [198]. Patients with MMD 
associated with other diseases have a higher perioperative complication rate than 
regular MMD patients [188].
Preoperative infarction is related to a greater risk of postoperative complica-
tions [232, 233].
Direct or combined BR is associated with better outcomes than indirect BR, 
particularly in the ischemic type MMD [140, 190, 205]. Meanwhile, for haemor-
rhagic strokes, there are no differences between direct, indirect or combined BR, 
and thus the indirect techniques are recommended because they are more accessible 
to perform [205].
The best collateral vessel formation results are obtained using a superficial 
temporal to MCA bypass combined with an EDAMS and lowest with EDAS [140]. 
Nevertheless, EDAS combined with multiple burr-holes can provide similar 
outcomes with a less technically demanding procedure and fewer postoperative 
negative events [159, 177].
Surgical BR in MMD can prevent future cerebrovascular insults and avoid 
cognitive decline [116, 117, 227]. It is indicated in asymptomatic patients at the 
slightest sign of disease progression or patient neurological or mental impairment 
[103, 234, 235], particularly in the paediatric age group [62, 103]. If performed 
early before irreversible damage, it can improve the neurological status and 
prevent the cognitive decline [103], stopping or at least slowing the progression of 
this nasty disease [136, 206, 234]. Ideally, in children, the surgical BR should be 
performed not later than three months after the first symptoms appear at a young 
age [190], the best before six years of age [106].
6. Conclusions
MMD is an uncommon cerebrovascular disorder with a higher frequency among 
people with Asian ancestry. Medical treatment is not helpful to stop the MMD pro-
gression and only can control minor symptoms but not ischemic nor haemorrhagic 
events. BR can improve brain vascularization, providing a collateral blood supply 
source that contains this nasty disease’s progression. Direct BR is more effective 
in adults and adolescents than in the paediatric population. Children benefit most 
from indirect BR. Combined BR improves the results from direct and indirect BR 
and can also be used as a rescue procedure. Although controversial, many surgeons 
posit that asymptomatic MMD patients should be submitted to preventive BR 
before irreversible brain damage happens.
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